Samsung Biologics has received the highest rating in a global environmental, social, and governance (ESG) assessment.
On November 4, Samsung Biologics announced that it achieved the top rating in Sustainalytics' '2026 ESG Risk Assessment.'
The company scored a total of 9 points, moving up from last year's 'Low Risk' to a 'Negligible' rating. Among the 842 companies evaluated in the global pharmaceutical sector, it ranked 4th.
Sustainalytics evaluates the non-financial risks and management levels of approximately 16,000 companies worldwide each year. The ratings are divided into five levels, with lower risk scores indicating better evaluations. The highest rating, 'Negligible,' is awarded to companies scoring below 10 points.
Samsung Biologics emphasized that this assessment recognized its efforts to enhance management systems across all ESG areas and to proactively expand information disclosure.
In the environmental sector, the company significantly strengthened its environmental management system by conducting environmental audits and developing plans for hazardous waste recycling.
In the social sector, it explained that it improved social responsibility and information transparency through the establishment of diversity policies and the disclosure of quality and safety goals. Additionally, in the governance sector, it received recognition for enhancing governance management systems through ethical audits and the establishment of board diversity goals.
John Lim, CEO of Samsung Biologics, stated, "We will continue to uphold responsible management and transparent information disclosure to further solidify the trust of global stakeholders."
On November 4, Samsung Biologics announced that it achieved the top rating in Sustainalytics' '2026 ESG Risk Assessment.'
The company scored a total of 9 points, moving up from last year's 'Low Risk' to a 'Negligible' rating. Among the 842 companies evaluated in the global pharmaceutical sector, it ranked 4th.
Sustainalytics evaluates the non-financial risks and management levels of approximately 16,000 companies worldwide each year. The ratings are divided into five levels, with lower risk scores indicating better evaluations. The highest rating, 'Negligible,' is awarded to companies scoring below 10 points.
Samsung Biologics emphasized that this assessment recognized its efforts to enhance management systems across all ESG areas and to proactively expand information disclosure.
In the environmental sector, the company significantly strengthened its environmental management system by conducting environmental audits and developing plans for hazardous waste recycling.
In the social sector, it explained that it improved social responsibility and information transparency through the establishment of diversity policies and the disclosure of quality and safety goals. Additionally, in the governance sector, it received recognition for enhancing governance management systems through ethical audits and the establishment of board diversity goals.
John Lim, CEO of Samsung Biologics, stated, "We will continue to uphold responsible management and transparent information disclosure to further solidify the trust of global stakeholders."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.